Allergic rhinitis is a common inflammatory disease condition
|
|
- Angela Bryan
- 6 years ago
- Views:
Transcription
1 Original Article An Open Label, Active Controlled, Multicentric Clinical Trial to Assess the Efficacy and Safety of Fluticasone Furoate Nasal Spray in Adult Indian Patients Suffering from Allergic Rhinitis Amit H Kubavat *, Prafulla Pawar *, Ravindra Mittal *, Vikas Sinha **, Umakant B Shah ***, Tarun Ojha, Narendra Khippal, Tushar Patel # Abstract Background: Allergic rhinitis is a common upper respiratory tract inflammation associated with a significant morbidity in all the age groups. Fluticasone furoate is a new potent topical glucocorticoid for the treatment of allergic rhinitis. Objective: To compare efficacy and safety of fluticasone furoate (FF) nasal spray 110 µg/day with fluticasone propionate (FP) nasal spray 200 µg/day for the relief of symptoms of allergic rhinitis in adult Indian patients. Methods: Clinically symptomatic patients (n=220) with allergic rhinitis received treatment with FF or FP for 2 weeks in this comparative, open label, multicentric, clinical trial. Nasal symptoms (nasal congestion, rhinorrhea, nasal itching, and sneezing) and ocular symptoms (itching/burning eyes, tearing/watering eyes, and eye redness) were recorded on a 4-point categoric scale by the patients. The efficacy was assessed by the change in nasal and ocular symptom scores as their subtotals (Total Nasal Symptom Score and Total Ocular Symptom Score) and grand total (Total Symptom Score). Results: FF produced significantly better improvement in Total Symptom Score (-10.4 ± 3.2 vs ± 3.5, p<0.005) and Total Nasal Symptom Score (-7.3 ± 2.2 vs ± 2.6, p<0.005) as compared to FP. Also a significantly larger percentage of patients achieved complete symptomatic relief with FF (45.3% vs. 31.4%, p<0.05). FF was also better tolerated than FP. Conclusion: FF nasal spray is significantly more effective and better tolerated than FP nasal spray for the treatment of allergic rhinitis in adult Indian patients. Introduction Allergic rhinitis is a common inflammatory disease condition of upper respiratory tract. The old classification of allergic rhinitis into seasonal or perennial is now replaced by a classification based on the duration of symptoms as persistent or intermittent along with severity of symptoms as mild or moderate-severe according to ARIA (Allergic Rhinitis & its Impact on Asthma) guidelines, which is currently accepted internationally to guide the medical treatment. 1 Its prevalence is about 10-40% among all age-groups in United States and other western countries. 2 Prevalence is reported to range from 10-13% in Delhi state of North India. 3 Also, symptoms of rhinitis are reported in 75% of children and 80% of asthmatic adults in India, while it still continues to be considered a trivial disease. 4 Though, it is not a life-threatening disease, it can significantly * Cadila Healthcare Ltd., Zydus Tower, 9th Floor, Satellite Cross-roads, Ahmedabad , Gujarat; ** Professor & Head, Dept. of ENT, M. P. Shah Medical College, Jamanagar; *** Professor & Head, Dept. of ENT, N. H. L. Municipal Medical College and Sheth V. S. General Hospital, Ahmedabad; Associate Professor, Dept. of ENT, Mahatma Gandhi National Institute of Medical Sciences, Jaipur; Associate Professor, Dept. of Chest & TB, S.M.S. Medical College & Hospital, Jaipur; # Consultant Pulmonologist & Critical Care Specialist, Allergy, Sleep Health, Respiratory & Intensive Care and Interventional Pulmonology Associates, Ahmedabad Received: ; Accepted: impair patient s quality of life and productivity. 5 In children also, physical, social, psychological well-being and academic performance is adversely affected by the illness. 6 Current therapeutic modalities for the management of allergic rhinitis include; H1 receptor antagonists (antihistamines), decongestants, mast-cell stabilizers, leukotriene receptor antagonists, corticosteroids and anti-cholinergic agents in oral or topical nasal formulations. Intranasal corticosteroids (INS) are considered to be a first line therapeutic option for the management of intermittent as well as persistent allergic rhinitis. 1 Fluticasone Furoate (FF) is a new topical glucocorticoid with a high relative receptor affinity, selectivity and potency as well as a long duration of anti-inflammatory activity in comparison to other glucocorticoids currently in usage. 7,8 It has a low absolute systemic bioavailability after intranasal administration 9 and does not affect hypothalamic-pituitary-adrenal (HPA) axis function at recommended doses in children 2 years of age to adults. 10,11 It has also been shown not to interfere with growth in pre-pubertal children in a short term study. 12 Several placebo controlled clinical trials have shown that FF consistently improves nasal as well ocular symptoms of seasonal/perennial allergic rhinitis at an optimal dose of 110 µg/day. 13,14 The efficacy and safety of FF is well established internationally in adults, adolescents and children aged 2 years. 15 The present study was conducted to demonstrate efficacy and 424 JAPI july 2011 VOL. 59
2 Fig. 1 : Flow diagram of the patients enrolled in the study safety of FF nasal spray 110 µg/day for the relief of nasal and ocular symptoms of allergic rhinitis in adult Indian patients in comparison with fluticasone propionate nasal spray 200 µg/day. Materials and Methods Patients Patients of either sex aged 18 years, and presenting with complaints of allergic rhinitis having nasal and/or ocular symptoms were screened for the study after taking their informed consent. Patients with severe physical nasal obstruction or injury, nasal ulcers, recent nasal surgery, asthma, rhinitis medicamentosa, acute or chronic sinusitis, glaucoma, cataract, any psychiatric disorder, adrenal insufficiency, bacterial or viral infection within 2 weeks of participation in the study were excluded from the study. Patients with measles, chickenpox, active or quiescent tuberculous infections of the respiratory tract, ocular herpes simplex and candida species infection of the nose were also not included. Patients with known hypersensitivity to fluticasone furoate or fluticasone propionate or any of the components of the medications, continuing history of alcohol and / or drug abuse and those who have participated in another clinical trial in the past 3 months were also excluded from the study. Pregnant and lactating women and persons suffering from significant uncontrolled disease of any body system were also not included in the study. Concomitant medication with any other antiallergic medications, corticosteroids (systemic or inhaled or intranasal), CYP3A4 inhibitors such as ketoconazole, ritonavir, etc. and use of ocular preparations (including artificial tears, eye wash/ irrigation solutions or lubricants) was not permitted during the study period. Procedures This open label, multicentric, comparative clinical study was approved by the Drugs Controller General of India (DCGI) and institutional/independent ethics committees of each of the participating centre. To determine symptom severity, patients rated their nasal (nasal congestion, rhinorrhea, nasal itching, and sneezing) and ocular (itching/burning eyes, tearing/watering eyes, and eye redness) symptoms at baseline on a 4-point categoric scale: 0 = none/ no symptoms; 1 = mild symptoms, but not affecting any activities during the day/sleep at night; 2 = moderate symptoms affecting at least one activity or disturbing sleep; 3 = severe symptoms affecting >2 daily activities or disturbing sleep all night or most of the night. For inclusion into the study, patients were required to be clinically symptomatic, with a total nasal symptom score (TNSS; the sum of all the 4 individual nasal symptom scores) of 6 or greater and/or a total ocular symptom score (TOSS; the sum of all the 3 individual ocular symptom scores) of 4 or greater. The symptoms assessed as well as the scale used are the same reflective patient reported outcomes used in clinical trials conducted with FF internationally. Patients were given diary cards in which they recorded severity of nasal and ocular symptoms as mentioned above on a daily basis. Symptoms were re-evaluated by the investigator at the end of one and two weeks of treatment. Patients were allocated to receive either 110 mg Fluticasone furoate once daily administered as 2 sprays (27.5 mg/spray) in each nostril or 200 mg Fluticasone propionate once daily administered as 2 sprays (50 mg/spray) in each nostril for the entire duration of the study i.e., 2 weeks. Hematological and biochemical investigations like complete haemogram, liver and renal function tests were done at the screening visit and at the end of treatment. Clinical adverse events, if any, were recorded at the end of week 1 and week 2, along with their nature, intensity, action taken, relationship to the study drug and outcome. All efficacy and safety assessments were carried out on the intent-to-treat population, which comprised all the enrolled patients who received at least 7 days treatment. The primary efficacy end point was the change in Total Symptom Score (TSS; the sum of TNSS and TOSS) at the end of study as compared to baseline. Secondary efficacy end points were the change in TNSS, TOSS and individual nasal and ocular symptom scores at the end of study as compared to baseline. Symptom scores are presented as mean ± SD. Statistical analysis was carried out using two-tailed t-test assuming unequal variance and chi-square test. Results Patients A total of 223 patients were screened in 5 centers, and 220 patients were found to be eligible for enrollment, who participated in this clinical trial in Indian patients 110 patients each in the Fluticasone furoate (FF) group and the Fluticasone propionate (FP) group. 106 (96.4%) patients in FF group and 105 (95.5%) patients in FP group were eligible for intention to treat efficacy analysis, while 110 (100%) patients in FF Group and 109 (99.1%) patients in FP Group were eligible for safety analysis as mentioned in materials and methods and Fig. 1. Demographic and baseline characteristics of the enrolled patients are shown in Table 1. Patients in both the groups were comparable in demographic characteristics and in severity of symptoms reflected as a similar TSS, TNSS and TOSS. Efficacy analysis For the primary efficacy endpoint (i.e. change in TSS at the end of study as compared to baseline), reduction in TSS was observed in both the groups; while a statistically significant reduction was noted in FF group (-10.4 ± 3.2) as compared to FP group (-8.9 ± 3.5) at the end of therapy (p < 0.005). The mean TSS reduced from 12.4 ± 3.5 at Day 0 to 2.0 ± 2.2 at Day 14 in FF JAPI july 2011 VOL
3 Table 1: Demographics and baseline characteristics of the patients Characteristics FF (n=110) FP (n=110) Age (y) Mean ± SD 35.2 ± ± 11.9 Minimum-maximum Sex, n (%) Female 32 (70.9%) 46 (58.2%) Male 78 (29.1%) 64 (41.8%) Height (cm) Mean ± SD ± ± 8.1 Minimum-maximum Weight (kg) Mean ± SD 64.5 ± ± 13.9 Minimum-maximum Duration of illness (y) Mean ± SD 6.7 ± ± 5.9 Minimum-maximum 3 months - 27 years 4 months - 30 years Baseline symptom scores, mean ± SD Nasal congestion 2.4 ± ± 0.8 Rhinorrhoea 2.2 ± ± 0.8 Nasal itching 1.9 ± ± 0.9 Sneezing 2.2 ± ± 0.8 Itching/burning eyes 1.5 ± ± 1.0 Tearing/watering eyes 1.3 ± ± 0.9 Eye redness 0.9 ± ± 0.9 TNSS 8.7 ± ± 1.6 TOSS 3.7 ± ± 2.2 TSS 12.4 ± ± 3.3 Table 2: Reduction in TNSS, TOSS and individual nasal & ocular symptom scores in both the study groups Symptom Scores (Reductions; Mean ± SD) FF (n=106) FP (n=105) p-value Nasal congestion ± ± 1.0 < 0.05 Rhinorrhoea ± ± 1.0 N.S. Nasal itching ± ± 0.8 < Sneezing ± ± 1.1 N.S. TNSS ± ± 2.6 < Itching/burning eyes ± ± 0.9 N.S. Tearing/watering eyes ± ± 0.8 < 0.05 Eye redness ± ± 0.8 N.S. TOSS ± ± 1.8 N.S. Table 3: The percentage of patients achieving a complete relief from allergic rhinitis symptoms at the end of study in both the groups Parameter FF (n=106) FP (n=105) Difference (FF-FP) Nasal congestion 54.7% 45.1% 9.6% Rhinorrhoea 67.7% 56.3% 11.4% Nasal itching 75.3% 61.0% 14.3% Sneezing 76.2% 60.6% 15.6% Itching/burning eyes 62.8% 51.8% 11.0% Tearing/watering eyes 78.8% 57.7% 21.1% Eye redness 79.0% 66.2% 12.8% TNSS 46.2% 32.4% 13.8% TOSS 53.3% 44.6% 8.7% TSS 45.3% 31.4% 13.9% Fig. 2 : Reduction in the mean TSS in both the study groups Group, while it decreased from 12.3 ± 3.3 at Day 0 to 3.4 ± 3.3 at Day 14 in FF Group as can be seen from Fig. 2. Patients attaining complete relief from all the nasal and ocular symptoms i.e. a total symptom score of zero during the course of the study were 45.3% in FF Group and 31.4% in FP group (p<0.05). In the secondary efficacy endpoints of change in TNSS, TOSS and individual nasal and ocular symptom scores at the end of therapy, reductions were observed in both the groups as shown in Table 2. A statistically significant reduction was observed in TNSS in FF group in comparison with FP group (p <0.05), while the reductions did not reach statistical significance for TOSS. In FF group, 46.2% and 53.3% patients achieved complete relief Fig. 3 : Investigators opinion on global assessment of efficacy from all the nasal and ocular symptoms respectively, while it was so in 32.4% and 44.6% patients in FP group at the end of study. The percentage of patients achieving a complete relief from individual nasal and ocular symptoms of allergic rhinitis is shown in Table 3. At the end of the study, all the investigators gave their overall assessment of efficacy to FF and FP on a 4-point rating scale as excellent, good, fair or poor. This comparative assessment according to global impression of symptomatic improvement is shown in Fig. 3. Safety analysis Safety to FF and FP was assessed by the estimation of 426 JAPI july 2011 VOL. 59
4 Sr. No. Table 4 : List of adverse events reported in both the study groups Nature of adverse event FF Group (n=110) No. of Incidence Events FP Group (n=109) No. of Incidence Events 1. Nasal irritation % 2. Headache 3 2.7% 3 2.7% 3. Cough 2 1.8% 2 1.8% 4. Sneezing % 5. Fever % 6. Giddiness % TOTAL 5 4.5% % laboratory parameters and adverse events recording as mentioned in materials and methods. None of the patients discontinued the study medication due to adverse event in either FF or FP group during the study. Further, 5 adverse events were reported by 5 (4.5%) patients in FF group and 13 adverse events were reported by 13 (11.9%) patients in FP group during the course of the study. The complete list of these adverse events is given in Table 4. All the 5 adverse events reported with FF were of mild intensity and 4 of them were considered to be related to FF use by the investigators. Out of 13 adverse events reported with FP, 4 and 9 events were of moderate and mild intensity respectively and were considered to be related to its usage. All the reported adverse events resolved completely, either spontaneously or by symptomatic treatment during the course of study. No serious adverse event was reported by any of the patients enrolled in either of the study group. Further, there was no significant alteration in any of the laboratory parameters as assessed at baseline and at the end of therapy with the study drug in any of the patients in this study. Discussion The present study was carried out to assess the comparative efficacy and safety of 2 intranasal corticosteroids (INS), Fluticasone Furoate and Fluticasone Propionate, for the treatment of allergic rhinitis in adult Indian patients. The results indicate that for the relief of both nasal and ocular symptoms of allergic rhinitis, FF is better as compared to FP, though a statistically significant difference was not found for each of the symptoms assessed. Complete symptomatic relief was reported in a higher percentage of patients treated with FP in comparison to FF treated patients. In terms of safety also, FF was shown to be better tolerated as compared to FP with a lower incidence and lesser severity of adverse events reported during the treatment. An earlier study has demonstrated non-inferiority of FF as compared to FP in patients with Japanese cedar pollinosis. 16 This study did show better resolution of symptoms of sneezing, rhinorrhoea and nasal congestion (3TNSS) with FF as compared to FP (-1.23 ± vs ± 0.142) but a direct statistical comparison was not made due to a non-inferiority trial design. A faster onset of action of FF from the 1 st day of treatment was demonstrated in this study as compared to FP. During our study also, it was noted that FF caused more reduction in total nasal as well as ocular symptom scores from Day 3 of assessment which was persistently better than FP during the entire course of study. Another study has compared patient preferences with regards to sensory attributes of FF and FP nasal sprays. 17 It was demonstrated that after single administration in adult patients with allergic rhinitis, FF have a preferable sensory attributes like odour, aftertaste, drip down the throat, nose run-off and overall than FP. Though this study demonstrated that FF can lead to a better patient compliance, it did not directly compare the efficacy and tolerability of both INS. Our study also showed a better patient tolerability of FF with a lesser incidence of drug related adverse events reported as compared to FP, which is consistent with the findings of the above study. Andrews CP et al conducted two comparative studies of FF with oral fexofenadine and placebo and reported that FF nasal spray is significantly more effective for the relief of night time nasal and ocular symptoms relative to both the comparators over a treatment period of 2 weeks. 18 Further, there are several placebo controlled studies conducted during the clinical development of FF and also thereafter, which have consistently showed therapeutic efficacy as well safety of FF nasal spray in a patient population ranging from children 2 years of age to adults, for which it has been approved internationally. 8,13-15,19,20 Limitations This study demonstrates the efficacy and safety of FF in Indian patients. The open label design of the study is likely to be affected by the investigator bias, which is inherent to all open label studies. However, trial design incorporating use of an active comparator that is current standard of care and patient reported outcomes as key primary and secondary efficacy variables ensure validity of the results of study. Conclusion The results of this open label, multicentric, active controlled clinical trial demonstrate that fluticasone furoate nasal spray, 110 µg/day is significantly more effective for the relief of nasal symptoms in adult patients suffering from allergic rhinitis when compared with fluticasone propionate nasal spray, 200 µg/day. Though, relief from ocular symptoms is better, the difference is not statistically significant. Moreover, fluticasone furoate also has a better tolerability profile and therefore is likely to enhance patient compliance to treatment. Based on these findings fluticasone furoate nasal spray can present a first-line treatment option for the treatment of allergic rhinitis in Indian patients. Acknowledgement Cadila Healthcare Ltd., Zydus Tower, 9 th Floor, Satellite Cross-roads, Ahmedabad , Gujarat. References 1. Brunton SA, Fromer LM. Treatment options for the management of perennial allergic rhinitis, with a focus on intranasal corticosteroids. South Med J 2007;100: Dykewicz MS, Fineman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol 1998;81: Gaur SN, Gupta K, Rajpal S, Singh AB, Rohtagi A. Prevalence of bronchial asthma and allergic rhinitis among urban and rural adult population of Delhi. Indian J Allergy Asthma Immunol 2006;20: Shah A, Pawankar R. Allergic rhinitis and co-morbid asthma: perspective from India - ARIA Asia-Pacific Workshop report. Asian Pac J Allergy Immunol 2009;27: Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108(1 Suppl):S45-S Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004;26: Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, et al. Pharmacological properties of the enhanced-affinity JAPI july 2011 VOL
5 glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-L Goyal N, Hochhaus G. Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc) 2008;44: Allen A, Down G, Newland A, Reynard K, Rousell V, Salmon E, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007;29: Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol 2008;100: Tripathy I, Levy A, Ratner P, Clements D, Wu W, Philpot E. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol 2009;20: Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther 2007;29: Giavina-Bianchi P, Agondi R, Stelmach R, Cukier A, Kalil J. Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Ther Clin Risk Manag 2008;4: Sorbera LA, Serradell N, Bolos J. Fluticasone Furoate. Drugs of the Future 2007;37: McCormack PL, Scott LJ. Fluticasone furoate: intranasal use in allergic rhinitis. Drugs 2007;67: Okubo K, Nakashima M, Miyake N, Komatsubara M, Okuda M. Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis. Allergy Asthma Proc 2009;30: Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther 2008;30: Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 2009;30: Nathan RA, Berger W, Yang W, Cheema A, Silvey M, Wu W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008;100: Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119: APICON Coimbatore Conference with difference API Conference comes to Coimbatore for the first time Coimbatore is known for hospitality, textiles and tourist spots apart from medical education Kindly reserve the dates Jan 31, Feb 1, 2, Please send id and other contact details Dr. Muruganathan Dr. A.R. Vijayakumar Dr. Isaac Christianmoses Dr. Avudiappan Org.Chairman Chairman api Coimbatore Org. Secretary Treasurer muruganathan@airtelmail.in drisaacmoses@yahoo.co.in JAPI july 2011 VOL. 59
6 JAPI july 2011 VOL
7 430 JAPI july 2011 VOL. 59
8 JAPI july 2011 VOL
9 432 JAPI july 2011 VOL. 59
Scottish Medicines Consortium
Scottish Medicines Consortium fluticasone furoate, 27.5 micrograms /actuation nasal (Avamys ) No. (544/09) GlaxoSmithKline 06 March 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationEFFICACY AND SAFETY OF OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS
EFFICACY AND SAFETY OF OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS PAUL H. RATNER 1 ; FRANK HAMPEL 2 ; AURORA BREAZNA 3 ; CYNTHIA F. CARACTA 3 ; SUDEESH
More informationFURAMIST Nasal Spray (Fluticasone furoate )
Published on: 21 Jan 2016 FURAMIST Nasal Spray (Fluticasone furoate ) Composition Each spray contains: Fluticasone furoate 27.5 mcg Dosage Form Aqueous intranasal spray Pharmacology Pharmacodynamics Fluticasone
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationPhototherapy in Allergic Rhinitis
Phototherapy in Allergic Rhinitis Rhinology Chair KSU KAUH Ibrahim AlAwadh 18\1\2017 MBBS, SB & KSUF Resident, ORL-H&N Background: Endonasal phototherapy can relieve the symptoms of allergic rhinitis
More informationDistribution The in vitro protein binding for Mometasone furoate was reported to be 98% to 99% in concentra on range of 5 to 500 ng/ml.
NOSATREX Composition Mometasone Furoate 0.05% w/w Spray Action Mechanism of Action Mometasone Nasal Spray 50 mcg is a cor costeroid demonstra ng potent an -inflammatory properties. The precise mechanism
More informationSafety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials
Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox, MD San Luis Potosí, Mexico Intranasal mometasone furoate
More informationEFFICACY AND SAFETY OF OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS
EFFICACY AND SAFETY OF OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS GARY GROSS 1 ; FRANK HAMPEL 2 ; AURORA BREAZNA 3 ; CYNTHIA F. CARACTA 3 ; SUDEESH K.
More informationClinical & Experimental Allergy
doi: 10.1111/j.1365-2222.2010.03654.x Clinical & Experimental Allergy, 41, 160 170 REVIEW Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationMedicine Review. Medicine / Trade name Azelastine and fluticasone / Dymista Manufacturer
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast East Anglia Medicines Information Service Medicine Review Medicine / Trade name Azelastine
More informationSEASONAL ALLERGIC RHINITIS NASAL SYMPTOMS AND QUALITY OF LIFE WITH OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY
SEASONAL ALLERGIC RHINITIS NASAL SYMPTOMS AND QUALITY OF LIFE WITH OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY GARY N. GROSS 1 ; GARY BERMAN 2 ; NIRAN J. AMAR 3 ; CYNTHIA F. CARACTA 4 ; SUDEESH K. TANTRY
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VERAMYST safely and effectively. See full prescribing information for VERAMYST. VERAMYST (fluticasone
More informationLatest advances in the management of childhood allergic rhinitis
Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures
More informationPRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray
PRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray NAME OF THE MEDICINE: Fluticasone furoate Structure: 21 F O 2 3 28 HO 19 1 10 5 4 O 20 S 18 12 O 11 13
More information1 FULL PRESCRIBING INFORMATION 2 1 INDICATIONS AND USAGE
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VERAMYST Nasal Spray safely and effectively. See full prescribing information for VERAMYST Nasal
More informationSYNOPSIS. A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT
Drug product: RHINOCORT AQUA Drug substance(s): Budesonide Edition No.: Final Study code: D5360C00703 Date: 8 November 2005 SYNOPSIS A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel
More informationAllergic rhinitis in India: an overview
International Journal of Otorhinolaryngology and Head and Neck Surgery Chandrika D. Int J Otorhinolaryngol Head Neck Surg. 217 Jan;3(1):1-6 http://www.ijorl.com pissn 244-929 eissn 244-937 Review Article
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.ijrrjournal.com E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Quantitative Nasal Eosinophilia: An Objective Tool to Optimize Intranasal
More informationAzelastine nasal spray: the treatment of choice for allergic rhinitis
PRESS RELEASE Azelastine nasal spray: the treatment of choice for allergic rhinitis An astonishing one quarter of the planet s population suffers from allergic rhinitis, living with the aggravating symptoms
More informationThis report will provide a review on the comparative clinical effectiveness and safety between intranasal triamcinolone and beclomethasone.
TITLE: Intranasal Triamcinolone versus Intranasal Beclomethasone for Acute and Chronic Sinus Inflammation: A Review of Comparative Clinical Effectiveness and Safety DATE: 29 January 2013 CONTEXT AND POLICY
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 09 Nov 2018 18:49:36 GMT) CTRI Number CTRI/2010/091/001300 [Registered on: 05/10/2010] - Last Modified On 12/03/2013 Post Graduate Thesis Type of Trial
More informationFLONASE (fluticasone propionate) Nasal Spray, 50 mcg
FLONASE (fluticasone propionate) Nasal Spray, 50 mcg For Intranasal Use Only. PRESCRIBING INFORMATION SHAKE GENTLY BEFORE USE. DESCRIPTION Fluticasone propionate, the active component of FLONASE Nasal
More informationAVAMYS PRODUCT MONOGRAPH. fluticasone furoate nasal spray mcg/metered spray. Corticosteroid for nasal use
PRODUCT MONOGRAPH Pr AVAMYS fluticasone furoate nasal spray 27.5 mcg/metered spray Corticosteroid for nasal use GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 www.gsk.ca Date of
More informationIntroduction. Jean Bousquet France
Introduction Jean Bousquet France The unmet medical need in allergic rhinitis management Disease management and efficacy assessment gaps Recommendation INS are recommended as the most effective treatment
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 WYSTAMM 1 mg/ml, oral solution 120 ml vial with syringe for oral administration (CIP: 34009 222 560
More informationNASONEX Aqueous Nasal Spray Mometasone Furoate. Schering-Plough
NASONEX Aqueous Nasal Spray Mometasone Furoate Schering-Plough COMPOSITION NASONEX Aqueous Nasal Spray is a metered-dose, manual pump spray unit containing a suspension of mometasone furoate. Each metered-dose
More information* A brighter future for allergic rhinitis patients Thursday 21 st March h h Leuven, Belgium
* A brighter future for allergic rhinitis patients Thursday 21 st March 2013 13.15h - 14.15h Leuven, Belgium *Carr et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationClinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013
1. Clinical Study Report RANDOMIZED, OPEN, PARALLEL GROUP, PHASE IIIB STUDY ON THE EVALUATION OF EFFICACY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY IN PAEDIATRIC PATIENTS WITH ATOPIC DERMATITIS, WITH OR WITHOUT
More informationDUONASE Nasal Spray (Azelastine hydrochloride + Fluticasone propionate)
Published on: 10 Jul 2014 DUONASE Nasal Spray (Azelastine hydrochloride + Fluticasone propionate) Composition DUONASE Nasal Spray Each spray delivers: Azelastine Hydrochloride BP 140 mcg Fluticasone Propionate
More informationAllergic Rhinitis. Abstract Allergic rhinitis is defined as an immunologic response moderated by IgE and is. Continuing Education Column
Allergic Rhinitis Hun Jong Dhong, M.D. Department of Otorhinolaryngology Head and Neck Surgery Sungkyunkwan University School of Medicine, Samsung Medical Center E mail : hjdhong@smc.samsung.co.kr Abstract
More informationPRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray
PRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray NAME OF THE MEDICINE: Fluticasone furoate Structure: 21 F O 2 3 28 HO 19 1 10 5 4 O 20 S 18 12 O 11 13
More informationPharmacotherapy for Allergic Rhinitis
Pharmacotherapy for Allergic Rhinitis William Reisacher, MD FACS FAAOA Assistant Professor Weill Cornell Medical College The Impact of Allergic Rhinitis Allergic rhinitis affects approximately 50 million
More informationALLERGIC RHINITIS Eve Kerr, M.D., M.P.H.
- 63-3. ALLERGIC RHINITIS Eve Kerr, M.D., M.P.H. We conducted a MEDLINE search of review articles on rhinitis between the years of 1990-1995 and selected articles pertaining to allergic rhinitis. We also
More informationFLONASE (fluticasone propionate) Nasal Spray, 50 mcg
FLONASE (fluticasone propionate) Nasal Spray, 50 mcg For Intranasal Use Only. PRESCRIBING INFORMATION SHAKE GENTLY BEFORE USE. DESCRIPTION Fluticasone propionate, the active component of FLONASE Nasal
More informationThe medicine is not currently marketed in New Zealand
Avamys Data Sheet (This Data Sheet contains all registered presentations of Avamys.) AVAMYS Nasal Spray NAME OF THE MEDICINE: Fluticasone furoate Structure: 21 F O 2 3 28 HO 19 1 10 5 4 O 20 S 18 12 O
More informationPRODUCT INFORMATION FLIXONASE ALLERGY & HAYFEVER 24 HOUR
PRODUCT INFORMATION FLIXONASE ALLERGY & HAYFEVER 24 HOUR NAME Fluticasone propionate DESCRIPTION FLIXONASE ALLERGY & HAYFEVER 24 HOUR Fluticasone Aqueous Nasal Spray (0.05 w/w) is an aqueous suspension
More informationAllergic Rhinitis: Effects on Quality of Life and Co-morbid Conditions
Disclosures : Effects on Quality of Life and Co-morbid Conditions Nycomed Pharmaceutical Sepracor Pharmaceutical Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee
More informationARIA. At-A-Glance Pocket Reference 2007
ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT
More informationPRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray
PRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray NAME OF THE MEDICINE: Fluticasone furoate Structure: 21 F O 2 3 28 HO 19 1 10 5 4 O 20 S 18 12 O 11 13
More informationHow Effective is Acupuncture in Treating Persistent Allergic Rhinitis in Children and Adults?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 How Effective is Acupuncture in Treating
More informationRandy Russell Assistant Director, Regulatory Affairs Alcon Research, Ltd South Freeway, R3-54 Fort Worth, TX
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 Randy Russell Assistant Director, Regulatory Affairs 6201 South Freeway, R3-54 Fort Worth,
More informationFURAMIST AZ Nasal Spray (Fluticasone furoate + Azelastine hydrochloride)
Published on: 27 Jan 2016 FURAMIST AZ Nasal Spray (Fluticasone furoate + Azelastine hydrochloride) Composition Each spray delivers: Azelastine Hydrochloride BP 140 mcg Fluticasone Furoate 27.5 mcg Dosage
More informationDerriford Hospital. Peninsula Medical School
Asthma and Allergic Rhinitis iti What is the Connection? Hisham Khalil Consultant ENT Surgeon Clinical Senior Lecturer, PMS Clinical Sub-Dean GP Evening 25 June 2008 Plymouth Derriford Hospital Peninsula
More informationPRINCIPAL MEDICATION OPTIONS FOR RHINITIS
SEE INDICATED SUMMARY STATEMENT (SS#) DISCUSSION FOR SUPPORTING DATA ALLERGIC RHINITIS (AR): SEASONAL (SAR) AND PERENNIAL (PAR) MONOTHERAPY ORAL Antihistamines, oral (H1 receptor antagonists) (SS# 61-64)
More informationTreatment Of Allergic Rhinitis
Treatment Of Allergic Rhinitis 1 / 6 2 / 6 3 / 6 Treatment Of Allergic Rhinitis Galphimia Glauca, Histaminum Hydrochlo-ride, Cardiospermum Halicacabum and Amni Visnaga are effective homeopathic medicines
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationElocon (mometasone furoate) Cream, Ointment, and Lotion Formulations : Core Safety Profile
Elocon (mometasone furoate) Cream, Ointment, and Lotion Formulations : Core Safety Profile 4.3 Contraindications Elocon is contraindicated in facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis,
More informationMANAGEMENT OF RHINOSINUSITIS IN ADOLESCENTS AND ADULTS
MANAGEMENT OF RHINOSINUSITIS IN ADOLESCENTS AND ADULTS Ministry of Health Malaysia Malaysian Society of Otorhinolaryngologist - Head & Neck Surgeons (MS)-HNS) Academy of Medicine Malaysia KEY MESSAGES
More informationORIGINAL ARTICLE. of the most common diseases,
ORIGINAL ARTICLE Rupatadine and Levocetirizine for Seasonal Allergic Rhinitis A Comparative Study of Efficacy and Safety Rituparna Maiti, MD; Jalelur Rahman, MBBS, MS; Jyothirmai Jaida, MD; Uma Allala,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCLINICAL POLICIES FORUM
Date of Meeting: 10 September 2013 CLINICAL POLICIES FORUM For: Note: To note Edits to Allergic Rhinitis Primary Care Pathway to reflect change in treatment group over 12 year olds Changes to text within
More informationDiagnosis and Treatment of Respiratory Illness in Children and Adults
Page 1 of 9 Main Algorithm Annotations 1. Patient Reports Some Combination of Symptoms Patients may present for an appointment, call into a provider to schedule an appointment or nurse line presenting
More informationProposal To reclassify Beconase Hayfever (beclomethasone 50 g/actuation) from Restricted Medicine to Pharmacy Medicine
Beconase Hayfever (Beclomethasone dipropionate, 50 per actuation) Proposal To reclassify Beconase Hayfever (beclomethasone 50 g/actuation) from Restricted Medicine to Pharmacy Medicine Background to current
More informationPharmacotherapy for Allergic Rhinitis
Disclosures: Pharmacotherapy for Allergic Rhinitis None John H. Krouse, MD, PhD, MBA Professor and Chairman Department of Otolaryngology-HNS Temple University School of Medicine Learning Objectives Describe
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET ALANASE Beclometasone dipropionate Aqueous Nasal Spray 50 µg & 100 µg per actuation Presentation ALANASE Aqueous Nasal Spray (50 micrograms per actuation) is an almost white opaque
More informationEfficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis
Ann Allergy Asthma Immunol 115 (2015) 325e329 Contents lists available at ScienceDirect Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis Philipp Badorrek,
More informationMontelukast: a better alternative than antihistaminics in allergic rhinitis
International Journal of Otorhinolaryngology and Head and Neck Surgery Kaur G et al. Int J Otorhinolaryngol Head Neck Surg. 017 Apr;():17- http://www.ijorl.com pissn -99 eissn -97 Original Research Article
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More informationAVAMYS TM NASAL SPRAY Fluticasone furoate
AVAMYS TM NASAL SPRAY Fluticasone furoate QUALITATIVE AND QUANTITATIVE COMPOSISTION AVAMYS Nasal Spray is a white, uniform suspension contained in an amber glass bottle, fitted with a metering (50 µl)
More informationLevocetirizine Hydrochloride Tablet Improves. the Nasal Conditions of Patients with Cedar Pollen. Allergy and Maintains their QOL
Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 7, 329-341 HIKARI Ltd, www.m-hikari.com Levocetirizine Hydrochloride Tablet Improves the Nasal Conditions of Patients with Cedar Pollen Allergy
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationAllergic Rhinitis. Dr. Sasan Dabiri. Otorhinolaryngologist Head & Neck Surgeon January 2011 Imam Hospital complex - Tehran
In the name of God Dr. Sasan Dabiri Otorhinolaryngologist Head & Neck Surgeon January 2011 Imam Hospital complex - Tehran Rhinitis Allergic Rhinitis Infectious Rhinitis Nonallergic Rhinitis Neoplastic
More informationA Winter Free of Cold Understanding the Common Cold and Flu. Camille Aizarani, MD Family Medicine Specialist
A Winter Free of Cold Understanding the Common Cold and Flu Camille Aizarani, MD Family Medicine Specialist Outline Introduction Is it a cold or flu? The Common Cold Symptoms of Common Cold Tansmission
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationALLERGIC RHINOSINUSITIS. Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences
ALLERGIC RHINOSINUSITIS Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences OVERVIEW Pathophysiology Goals of therapy Approaches to therapy Antihistaminics Corticosteroids
More informationFluticasone furoate (Avamys): new intranasal steroid spray Steve Chaplin MSc, MRPharmS
Fluticasone furoate (Avamys): new intranasal steroid spray Steve Chaplin MSc, MRPharmS KEY POINTS Avamys is a metered-dose nasal spray containing 27.5µg fluticasone furoate per dose indicated for the treatment
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationEfficacy and safety of montelukast in adults with asthma and allergic rhinitis
Respiratory Medicine (26), 1952 1959 Efficacy and safety of montelukast in adults with asthma and allergic rhinitis J.Chr. Virchow a,, C. Bachert b a Universität Rostock, Ernst-Heydemann-Str. 6, 1857 Rostock,
More informationAUSTRALIAN PRODUCT INFORMATION. AVAMYS (fluticasone furoate) NASAL SPRAY
AUSTRALIAN PRODUCT INFORMATION AVAMYS (fluticasone furoate) NASAL SPRAY 1 NAME OF THE MEDICINE Fluticasone furoate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION AVAMYS Nasal Spray is a white suspension of
More informationDrug Class Review on Nasal Corticosteroids
Drug Class Review on Nasal Corticosteroids Final Report Evidence Tables June 2006 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to
More informationTherapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with Seasonal Allergic Rhinitis
Allergology International. 2008;57:247-255 DOI: 10.2332allergolint.O-07-515 ORIGINAL ARTICLE Therapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with
More informationThe Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationFormat. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intranasal phototherapy for allergic rhinitis Allergic rhinitis is inflammation
More informationEfficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis
Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Manju K Mathew et al. Efficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis Keywords:
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Xhance GENERIC NAME Fluticasone propionate MANUFACTURER Optinose DATE OF APPROVAL September 18 th, 2017 PRODUCT LAUNCH DATE 1 Second quarter of 2018 REVIEW TYPE Review type 1 (RT1): New Drug
More informationRhinocort Aqua 32 micrograms/dose nasal spray, suspension Rhinocort Aqua 64 micrograms/dose nasal spray, suspension
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Rhinocort Aqua 32 micrograms/dose nasal spray, suspension Rhinocort Aqua 64 micrograms/dose nasal spray, suspension 2. QUALITATIVE
More informationMonocast Description Indications
Monocast Tablet Description The active ingredient of Monocast tablet is Montelukast Sodium INN. Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl
More information2018/6/20 Avamys - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Avamys Summary of Product Characteristics Updated 11-Jul-2017 GlaxoSmithKline UK 1. Name of the medicinal product AVAMYS 27.5 micrograms/spray, nasal spray suspension 2. Qualitative and quantitative composition
More informationScottish Medicines Consortium
Scottish Medicines Consortium Standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate (Grazax ) No. (367/07) ALK-Abellό Ltd 6 April 2007 The Scottish
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : FEXOFENADINE Study number : PJPR0024 Study title : A double-blind, randomized, placebo-controlled, parallel study comparing the efficacy and safety of three dosage strengths of MDL 16,455A
More informationIntroduction. Methods. Results 12/7/2012. Immunotherapy in the Pediatric Population
12/7/212 Introduction Immunotherapy in the Pediatric Population Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee Health Science Center Memphis, Tennessee Allergen
More informationAllergic Rhinitis 6/10/2016. Clinical and Economic Impact. Clinical and Economic Impact. Symptoms. Genetic/Environmental factors
I have no disclosures to make other than I too suffer from allergic rhinitis Allergic Rhinitis Betsy Close, MD Assistant Professor UT College of Medicine, Department of Family Medicine Clinical and Economic
More informationPATIENT INFORMATION NASONEX [nā-zə-neks] 50 mcg (mometasone furoate monohydrate) Nasal Spray For Intranasal Use Only Read the Patient Information
PATIENT INFORMATION NASONEX [nā-zə-neks] 50 mcg (mometasone furoate monohydrate) Nasal Spray For Intranasal Use Only Read the Patient Information that comes with NASONEX before you start using it and each
More informationAnti-allergic Effect of Bee Venom in An Allergic Rhinitis
Anti-allergic Effect of Bee Venom in An Allergic Rhinitis Dr: Magdy I. Al-Shourbagi Sharm International Hospital Allergic Rhinitis Rhinitis: Symptomatic disorder of the nose characterized by itching, nasal
More information13.2 Elements for a Public Summary
13.2 Elements for a Public Summary 13.2.1 Overview of disease epidemiology The common cold is one of the most prevalent diseases in humans and is the most common condition for which family doctors are
More informationFluticasone furoate Avamys 27.5mcg per actuation Nasal Spray
Fluticasone furoate Avamys 27.5mcg per actuation Nasal Spray PRODUCT DESCRIPTION Fluticasone furoate (Avamys ) Nasal Spray is a white, uniform suspension contained in an amber glass bottle, fitted with
More informationLIVOSTIN Eye Drops and Nasal Spray
LIVOSTIN Eye Drops and Nasal Spray PRODUCT INFORMATION NAME OF DRUG Levocabastine hydrochloride DESCRIPTION Levocabastine, (-)-[3S-[1(cis), 3 alpha, 4 beta]]-1-[4-cyano-4-(4-fluorophenyl) cyclohexyl]-3-
More informationAs-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy detineo, BSN, Lauran Haney, BSc, Christopher Blair, BSc, and Robert
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis
Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Stahl E, van Rompay W, Wang E C, Thomson D M Record
More informationPage 1 of 21. nostril once daily Children (2-11 yrs.): 1 spray in each nostril once daily Prophylaxis of Seasonal Allergic Rhinitis (2.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MOMETASONE FUROATE NASAL SPRAY safely and effectively. See full prescribing information for MOMETASONE
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More informationDiagnosis and Treatment of Respiratory Illness in Children and Adults Guideline
Member Groups Requesting Changes: Lakeview Clinic Marshfield Clinic Mayo Clinic South Lake Pediatrics Response Report for Review and Comment January 2013 Diagnosis and Treatment of Respiratory Illness
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More information